T
Tvardi Therapeutics
A clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases
About Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical firm established in 2017 and headquartered in Houston, Texas. The company was founded by Dr. Ron DePinho, former president of the MD Anderson Cancer Center, and Dr. David Tweardy, who leads the internal medicine division at the same institution. Their collective experience in oncology and internal medicine provides a strong scientific foundation for the company's focus. Tvardi operates in the biopharmaceutical market, concentrating on the development of orally-delivered small molecule inhibitors that target STAT3, a protein implicated in the progression of various cancers and fibrosis-driven diseases. The company's business model is centered on advancing its drug candidates through rigorous clinical trials to address significant unmet medical needs. As a clinical-stage entity, Tvardi's revenue generation is anticipated upon the successful commercialization of its products, with its financial runway supported by significant funding rounds and strategic partnerships.
The company's lead product candidate, TTI-101, is an oral STAT3 inhibitor designed to block the protein's activation, thereby inhibiting tumor growth and fibrotic processes. TTI-101 binds to the SH2 domain of STAT3, a mechanism intended to prevent its phosphorylation and subsequent disease-driving functions while preserving its necessary mitochondrial activities. This drug has been evaluated in a Phase 1 trial for advanced solid tumors, demonstrating a favorable safety profile and clinical activity. Tvardi is now conducting Phase 2 clinical trials for TTI-101 in patients with idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). The FDA has granted TTI-101 Orphan Drug Designation for both IPF and HCC, as well as Fast Track Designation for HCC, which could expedite its review process. Beyond its primary candidate, Tvardi is also developing a second-generation STAT3 inhibitor, TTI-109, which has completed IND-enabling studies.
Tvardi's journey began with a $9 million Series A financing in 2018, which funded the initial Phase 1 trial of TTI-101. A significant milestone was achieved in June 2021 with a $74 million Series B financing round, co-led by investors including Slate Path Capital, Palkon Capital, and ArrowMark Partners. This funding was pivotal for advancing the drug pipeline into mid-stage trials. In a strategic move to secure public company status and further funding, Tvardi completed a merger with Cara Therapeutics in April 2025, and its stock began trading on Nasdaq under the ticker TVRD. The company is led by CEO Imran Alibhai, Ph.D., who brought experience from DNAtrix and Alexandria Venture Investments upon joining in late 2018. The scientific advisory board includes notable figures like Nobel laureate James Allison, Ph.D.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2024 | $0 | — | Cara Therapeutics | ↗ |
| SERIES BOther financing | Jun 2021 | $74M | $296M | Sporos Bioventures · Palkon Capital · ArrowMark Partners · Slate Path Capital | — |
Growth signals
Latest recorded traffic for Tvardi Therapeutics is 4.7K monthly website visits, up 193.8% over the last three months. Tvardi Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tvardi Therapeutics in the Houston ecosystem
The Tvardi Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
National Institutes of Health
Cancer Prevention and Research Institute of Texas (CPRIT)
V Foundation
Series A5 investors entered at this stage
Sporos Bioventures
Palkon Capital- APArrowMark Partners
Slate Path Capital- 6C683 Capital
Other known investors2 additional known investors
Cara Therapeutics
University of Texas Health Science Center at Houston
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tvardi Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tvardi Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









